PPARG and cancer: Defects in PPARγ, signaling its altered expression and/or activation, as well as polymorphisms/mutations, are implicated in different pathological conditions occurring in metabolic syndrome, such as insulin resistance, obesity [10], dyslipidemia, and hypertension, that markedly increase the risk of type 2 diabetes [11–13], as well as cardiovascular diseases and cancer [3, 4, 14–17].